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during acute renal allograft rejection.
Background. In inflammation, urokinase plasminogen acti-
vator (uPA) and its receptor (uPAR) play an important role
in fibrinolysis and in activation and chemotaxis of neutrophils
and lymphocytes. Moreover, the uPA/uPAR system is involved
in processes that affect turnover of the extracellular matrix
(ECM). The aim of this study was to determine the local and
systemic release of uPAR, and the expression of uPA and
uPAR in renal tissues during acute renal allograft rejection.
Methods. Blood, urine, and tissue samples were collected
from 33 patients diagnosed with acute allograft rejection and
from 14 transplant patients without rejection. From 10 healthy
volunteers, blood and urine were collected as a control. In
urine and blood samples, the levels of uPAR were determined
by enzyme-linked immunosorbent assay (ELISA). Immuno-
staining and in situ hybridization for uPA and uPAR were
performed on renal biopsies.
Results. uPAR was detectable at low levels in serum and
urine of healthy volunteers and was increased in nonrejecting
allograft recipients. Serum and urine levels of uPAR were
higher in transplant recipients with rejection compared to non-
rejectors. The urine and serum levels of uPAR correlated with
the renal function. Immunostaining and in situ hybridization
showed an up-regulation of both uPA and uPAR in rejection
biopsies. Nonrejected grafts displayed no expression of uPA
and uPAR by immunostaining, or of uPAR by in situ hybridiza-
tion. uPA was detected in a limited number of tubular epithelial
cells by in situ hybridization. During rejection, lymphocytes as
well as tubular epithelial cells showed uPA and uPAR expres-
sion. In the vascular types of rejection, strong expression of
uPA was also seen in the entire vessel wall, while uPAR was
expressed by the endothelium.
Conclusion. This study shows that (1) uPA and uPAR are
up-regulated during acute renal allograft rejection; (2) uPAR
levels in urine and serum correlate with serum creatinine levels,
and (3) uPA and uPAR are produced by inflammatory cells,
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tubular epithelium, and vascular endothelium during acute re-
nal allograft rejection.
Despite the introduction of successful immunosup-
pressive drug therapies, acute renal allograft rejection
still occurs in 40% to 60% of patients after cadaveric
renal transplantation and causes graft loss in up to 4%
in the first year after transplantation [1, 2]. Histopatho-
logically, acute rejection is characterized by an inflam-
matory infiltrate, consisting mainly of T lymphocytes,
located in the interstitium, tubular epithelium, and, as
type and severity of rejection change, vascular endothe-
lium [3]. In recent years, the complex molecular mecha-
nisms underlying the activation and extravasation of lym-
phocytes into the allograft have been largely unraveled
[4, 5].
Components of the fibrinolytic system have recently
been recognized as major players in the recruitment of
inflammatory cells. The fibrinolytic system consists of
two serine proteases, the tissue-type plasminogen activa-
tor (tPA) and the urokinase-type plasminogen activator
(uPA), that both facilitate the conversion of plasminogen
into plasmin, which is the crucial protease in fibrinolysis
[6]. tPA is mainly involved in intravascular thrombolysis,
whereas uPA mediates a number of other functions,
including cell migration, pericellular proteolysis, tissue
remodeling, and fibrosis. The activity of both PAs is
inhibited by plasminogen activator inhibitors (PAI) type
1 and, to a lesser extent, type 2 [7]. uPA exerts most of
its effects via interaction with the urokinase PA receptor
(uPAR, CD87). uPAR, a glycosyl-phosphatidylinositol
(GPI)-anchored molecule that was first described in 1985
[8], is present at the cell surface of a wide variety of
different cell types, such as monocytes, macrophages,
neutrophils, T cells, endothelial cells, smooth muscle
cells, and renal tubular epithelial cells [9–14].
Beside their contribution to fibrinolysis, uPA and its
receptor play an important role in the activation and
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chemotaxis of neutrophils, macrophages, and lympho-
cytes through interaction with several integrins [15–18].
Furthermore, the uPA/uPAR system is involved in a
variety of processes that are associated with turnover
of the extracellular matrix (ECM), such as tumor cell
invasion and dissemination, angiogenesis, wound heal-
ing, and embryogenesis [16, 18–21]. This effect is partly
due to the generation of matrix metalloproteinases
(MMPs) by plasmin [22, 23]. So, activation of the uPA/
uPAR system not only initiates chemotaxis and extrava-
sation of inflammatory cells, but also leads to pericellular
proteolysis, thus facilitating the penetration of these cells
into the inflamed tissue.
On the other hand, the fibrinolytic system is also sup-
posed to play an important role in the prevention of both
glomerular and tubulointerstitial fibrosis, by diminishing
the accumulation of tubulointerstitial matrix through the
induction of plasmin and MMPs [24, 25]. Several studies
on components of the fibrinolytic system in the diseased
kidney have been performed. An up-regulation of glo-
merular uPAR expression has been described in renal
thrombotic microangiopathy and in a murine model of
nephrotoxic nephritis [26, 27]. Also, in crescentic glomer-
ulonephritis, an up-regulation of uPA was shown [28].
Studies using tPA knockout mice have shown a protec-
tive effect of plasminogen and tPA against acute in-
flammatory injury in a model of crescentic glomerulone-
phritis [29]. Recently, we described a local and systemic
release of uPAR in kidneys from patients with pyelone-
phritis [30].
A limited number of studies deal with the involvement
of the fibrinolytic system in renal allograft rejection, the
majority of which concern chronic rejection. A correla-
tion between renal allograft function and uPA protein
expression was first described by Bukovsky et al [31],
but a possible relationship between uPA/uPAR expres-
sion and acute rejection has not been studied in detail
up to now. However, up-regulation of uPA, uPAR, and
PAI-1 in chronically rejected kidneys has been reported
[32–34], suggesting that the fibrinolytic system plays an
important role in tissue remodeling within the chronically
rejected graft and the development of fibrosis, one of the
major histopathologic features of chronic rejection.
The aim of the present study was to determine the
local and systemic release of uPAR, the expression of
uPA and uPAR in renal tissues during acute renal allo-
graft rejection, and to correlate these data with renal
transplant function and with severity of rejection.
METHODS
Patients
Thirty-three patients with biopsy-proven acute renal
allograft rejection were selected randomly from the pa-
tient population of the Academic Medical Center of the
University of Amsterdam. These patients were divided
into three groups in accordance with the severity of the
rejection, using the Banff criteria for acute renal allograft
rejection [3] (type 1, 14 patients; type 2, 9 patients; and
type 3, 10 patients). All biopsies contained at least seven
glomeruli and two arteries. As control, 14 transplant
patients who showed no clinical or histopathologic evi-
dence of acute or chronic allograft rejection were se-
lected at random from a total population of 200 trans-
plant patients, undergoing protocol graft biopsy several
months after transplantation according to a research pro-
tocol. The protocol had been approved by the Medical
Ethical Committee of the Academic Medical Center of
the University of Amsterdam, and each patient had given
written informed consent.
Urine and serum samples from all patients were col-
lected at the time of biopsy. The main clinical data of
all patients are summarized in Table 1. Urine and serum
samples were also obtained from a control group of 10
nontransplanted healthy volunteers.
Enzyme-linked immunosorbent assay (ELISA)
uPAR concentrations in urine and serum were mea-
sured by ELISA according to the manufacturer using
purified mouse antihuman uPAR monoclonal antibody
(mAb) (4 g/mL) (R&D systems, Abingdon, UK) as
coating antibody, biotinylated goat-antihuman uPAR
antibody (100 ng/mL) (R&D systems) as detecting anti-
body, and recombinant human uPAR (R&D systems) as
standard. The detection limit of the assay was 0.2 ng/mL.
Urine concentrations are expressed asg/mmol creatinine
in order to correct for dilution and renal function.
Immunohistochemical studies
Immunohistochemical studies were performed on
cryostat sections (4 m thickness). After fixation in ace-
tone for 15 minutes at 4C, slides were washed, preincu-
bated first in 10% normal goat serum for 15 minutes,
and then incubated for 16 hours at 4C with mouse IgG2
antihuman uPAR mAb (CD87) (American Diagnostica
Inc., Greenwich, CT, USA) or IgG1 anti-uPA mAb
(American Diagnostica). Endogenous peroxidase activ-
ity was then blocked using 0.1% NaN3 and 0.3% H2O2
in phosphate-buffered saline (PBS) for 10 minutes at
room temperature. Sections were washed and incubated
with polymerized horseradish peroxidase (HRP)-conju-
gated goat antimouse IgG antibody (Powervision; Im-
munovision Technology, Daly City, CA, USA). Enzyme
activity of HRP was finally detected using 3-amino-9-ethyl-
carbazol (Sigma, Zwijndrecht, The Netherlands) and
counterstained with hematoxylin.
In situ hybridization
uPA and uPAR-specific digoxigenin (DIG)-labeled
riboprobes for in sity hybridization were prepared by
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Table 1. Clinical parameters of the included patients
No rejection AR type 1 AR type 2 AR type 3
Number of patients (M/F) 14 (7/7) 14 (8/6) 9 (4/5) 10 (6/4)
Age years (meanSD) 51.512.4 37.713.5 43.912.5 49.513.7
Donor characteristics
Age in years (meanSD) 47.915.0 3719.2a 37.813.2 46.117.4
Cadaveric 10 6a 5 10
Living related 3 3a 3 0
Living unrelated 1 1a 1 0
Serum creatinine at time of biopsy lmol/L (meanSD) 189200 447396 510505 568293b
Creatinine clearance at 1 year first post transplant year mL/min 73.724.1 62.426.0 65.822.5 40.021.1c
(meanSD)
First episode of rejection days (mean post transplantSD) Not applicable 18.824.0 10.54.2 20.813.4
Time of biopsy days (mean post transplantSD) 109115 5189 115 5780
Drug regimen
P 14/14 14/14 9/9 10/10
C 0/14 14/14 9/9 10/10
MMF 14/14 0/14 0/9 2/10
A 0/14 3/14 3/9 3/10
B 14/14 0/14 0/9 0/10
T 6/14 1/14 0/9 2/10
Graft outcome at 1 year
Adequate graft function 14 (100%) 9 (64%) 7 (78%) 6 (60%)
Graft loss — 5 (36%) 2 (22%) 4 (40%)
Abbreviations are: AR, acute rejection; P, prednison; C, cyclosporin; MMF, mycophenolate mofetil; A, azathioprine; B, basiliximab; T, tacrolimus.
a The characteristics of four donors from this group were unknown.
b Mean creatinine level at time of biopsy was significantly higher compared to the non rejecting group, P  0.05 determined by analysis of variance (ANOVA),
followed by a Dunnett’s T3 post hoc test.
c The mean creatinine clearance in this group was significantly lower compared to the other patient groups, P  0.05 determined by ANOVA, followed by a
Bonferroni post hoc test.
T7 RNA polymerase driven in vitro transcription, from
cloned-specific polymerase chain reaction (PCR) prod-
ucts as template. Briefly, cDNA was prepared on total
RNA extracted from human placenta using random
hexamer priming. Primers used in the PCR reaction
were 5-GAGAATTCACCACCATCGAGAA-3, and
5-TAATACGACTCACTATAGGGCCAGTGATCT
CACAGCTTGTG-3 for uPA, yielding a 426 bp product;
and 5-TCATCAGACATGAGCTGTGAGAG-3 and
5-TAATACGACTCACTATAGGGTACTGGACAT
CCAGGTCTGG-3 for uPAR, yielding a 563 bp prod-
uct. The underlined primer regions encode the T7-pro-
moter element. PCR products were cloned and clones
were identified by sequencing using an ABI sequencer
(Perkin Elmer Corp., Norwalk, CT, USA) with a dye-
terminator cycle-sequencing kit (Perkin Elmer Corp.).
After purification by phenol-extraction, isolated inserts
were used as a template in an in vitro transcription reac-
tion using T7 polymerase (DIG-RNA Labeling Kit;
Roche Diagnostics, Mannheim, Germany).
Using these probes, in situ hybridization was per-
formed as follows: 7 m thick sections were deparaffin-
ized, digested with 20 g/mL proteinase K (Invitrogen,
Life Technologies, Breda, The Netherlands) for 15 min-
utes at 37C, treated with 0.2% glycine (Merck, Amster-
dam, The Netherlands) for 5 minutes, and postfixed with
2% paraformaldehyde (Merck) and 0.1% glutaralde-
hyde (Merck) in PBS for 20 minutes. After pretreatment
with hybridization solution containing 50% formamide
(Merck), 5 standard sodium citrate (SSC) (Invitrogen,
Life Technologies), 1% Blocking Reagent (Roche, Alm-
ere, The Netherlands), 5 mmol/L ethylenediaminetetra-
acetic acid (EDTA) (Sigma, Zwijndrecht, The Nether-
lands), 0.1% Tween-20 (Sigma), 0.1% CHAPS (Sigma),
0.1 mg/mL heparin (BD Biosciences, Alphen aan den
Rijn, The Netherlands), and 1 mg/mL yeast tRNA (In-
vitrogen, Life Technologies), the sections were subjected
to hybridization. The DIG-labeled riboprobes (final con-
centrations 250 ng/mL uPA and 400 ng/mL uPAR) were
added to above-mentioned hybridization solution. Hy-
bridization was performed in a stove for 18 hours at
70C. After hybridization, the slides were washed with
2 SSC containing 50% formamide at 65C. After wash-
ing with 0.1% Tween-20 in PBS, they were treated with
2% Blocking Reagent (Roche), 10% normal goat serum,
and 0.1% Tween-20 in PBS for 30 minutes. Hereafter,
they were incubated with alkaline phosphatase-conju-
gated F(ab) fragments of sheep anti-DIG antibody
(Roche); bound alkaline phosphatase activity was visual-
ized with nitroblue tetrazolium chloride and 5-bromo-
4-chloro-3-indolylphosphate, toluidine salt (NBT/BCIP)
(Roche). Subsequently, a picro sirius red counterstaining
was performed. Slides were rinsed in tap water and
mounted with glycergel (Dako, Glostrup, Denmark).
All slides were coded and judged by two independent
pathologists who were unaware of the codes.
Statistical analysis
Data were analyzed by analysis of variance (ANOVA),
followed by a Bonferroni post hoc test or Dunnett T3 test
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Table 2. Histologic characteristics of the biopsies
Banff classification No rejection Type 1 Type 2 Type 3
Number of glomeruli (mean  SD) 16  9 11  6 14  8 13  6
Scorea 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Tubulitis 14 0 0 0 0 6 4 4 0 4 5 0 0 4 2 4
Interstitial inflammation 14 0 0 0 0 10 4 0 0 2 5 2 0 4 6 0
Glomerulitis 14 0 0 0 12 1 1 0 8 1 0 0 5 5 0 0
Arteriolar hyaline thickening 14 0 0 0 14 0 0 0 8 1 0 0 10 0 0 0
Intimal arteritis 14 0 0 0 12 1 0 1 0 7 2 0 0 0 0 10
Allograft glomerulopathy 13 1 0 0 14 0 0 0 9 0 0 0 10 0 0 0
Interstitial fibrosis 11 3 0 0 12 2 0 0 9 0 0 0 9 1 0 0
Tubular atrophy 14 0 0 0 10 4 0 0 7 2 0 0 9 1 0 0
Intimal thickening 13 1 0 0 13 1 0 0 8 1 0 0 10 0 0 0
Mesangial matrix increase 13 1 0 0 13 0 0 1 9 0 0 0 10 0 0 0
a Kidney biopsies were scored according to the Banff classification [3].
when appropriate, using the SPSS software. Differences
were regarded as statistically significant at P  0.05.
RESULTS
Association between clinical data and
histologic diagnosis
The clinical and biochemical characteristics of the pa-
tients are summarized in Table 1. The patients were
divided into four groups, according to the histopatho-
logic diagnosis: (1) no rejection (N  14 patients), (2)
acute rejection type 1 (N  14 patients), (3) acute rejec-
tion type 2 (N 9 patients), and (4) acute rejection type
3 (N 10 patients). No statistically significant differences
were observed among the four groups for age, gender,
age of kidney donor, time of first rejection episode (when
applicable), and time of biopsy. The mean serum creati-
nine value at the time of biopsy was not significantly
different, except in the type 3 group vs. the nonrejecting
group, namely 568  93 mol/L vs. 189  200 mol/L
(P  0.05 determined by ANOVA, followed by a Dun-
nett T3 post hoc test).
As summarized in Table 1, all patients received immu-
nosuppressive therapy based on prednisone and cyclo-
sporine. Three patients in every rejection group received
azathioprine. All nonrejectors and two patients in the
type 3 rejection group received mycophenolate mofetil.
Further, all nonrejectors were treated with basiliximab,
an interleukin-2 (IL-2) receptor antagonist. Six of the
nonrejectors, one patient from the type 1 rejection group,
and two from the type 3 rejection group received tacrol-
imus.
The histologic findings are summarized in Table 2.
Secretion of uPAR in serum and urine during
acute rejection
The urokinase receptor uPAR was detectable at low
levels in serum (2.6  0.2 ng/mL) and urine (679  80
ng/mmol creatinine) of healthy volunteers. As shown in
Table 3. Levels of unokinase plasminogen activator receptor
(uPAR) in serum and urine
uPAR in uPAR in urine
Groups serum ng/mL lg/mmol creatinine
Healthy subjects 2.630.15 0.680.08
No Rejection 5.100.75a 5.821.35a
Acute rejection, all types 8.411.04b 10.922.34b
Levels of uPAR in serum and urine. Data are displayed as mean  SEM of
the individual serum and urine concentrations of uPAR in healthy subjects (N 
10), transplant patients with adequate graft function and no evidence of rejection
(N  14), and all pooled rejection patients (N  33).
aP  0.05 compared to healthy subjects; bP  0.05 compared to the
non rejection group. Both P values were determined by analysis of variance
(ANOVA), followed by a Dunnett’s T3 post hoc test.
Table 3, both serum and urine levels of uPAR were
significantly higher in transplant recipients with stable
renal function in comparison with healthy controls. A
further increase in uPAR level was measured in serum
and urine of patients with acute rejection. As shown in
Figure 1, the urine and serum levels of uPAR correlated
with the renal function, determined by mean creatinine
levels in the blood (serum R  0.68, P  0.01; urine
R  0.50, P  0.01; Spearman rho test). Furthermore,
a correlation was found between the urine and serum
levels of uPAR in all groups (R  0.71, P  0.01; Spear-
man rho test), as is shown in Figure 2.
Further, we attempted to correlate the serum and
urine uPAR levels with the severity of renal rejection
as defined by the Banff classification. As shown in Figure
3, serum and urine uPAR levels seemed to correlate
with the severity of the rejection, although only for type
3 significant differences could be measured.
These data indicate that uPAR production is up-regu-
lated after renal transplantation and is significantly fur-
ther up-regulated during acute rejection episodes.
Immunostaining for uPA and uPAR
In order to localize the expression of uPA and uPAR,
all kidney biopsies (N  47) were stained for both mole-
cules by immunohistochemistry. Subsequently, all slides
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Fig. 1. Correlation between urokinase plasminogen activator receptor
(uPAR) level in serum (A), in urine (B), and the serum creatinine
concentration. Serum and urine levels of uPAR were determined by
enzyme-linked immunosorbent assay (ELISA). The urine and serum
levels of uPAR correlate with the renal function, determined by mean
creatinine levels in the blood (serum R  0.68, P  0.01; urine R 
0.50, P  0.01; Spearman rho test).
were judged by two independent pathologists who were
blinded for diagnosis. Representative images are shown
in Figure 4A to F. In the renal biopsies from the group
of patients without rejection no positive immunostaining
for uPA (Fig. 4A) and uPAR (Fig. 4D) was observed.
In biopsies from patients with rejection, the mononu-
clear infiltrate was strongly positive for uPAR (Fig. 4E)
and weakly for uPA (Fig. 4B). The damaged tubular
epithelium was also strongly positive for uPA (Fig. 4B).
In these biopsies, the staining was predominantly cyto-
plasmic. In the biopsies with acute rejection type 2 and
type 3, the endothelium strongly expressed both uPA
(Fig. 4C) and uPAR (Fig. 4F). uPA was predominantly
Fig. 2. Correlation between urokinase plasminogen activator receptor
(uPAR) levels in serum and urine. The urine and serum levels of uPAR
show a significant correlation in all groups (R 0.71, P 0.01; Spearman
rho test).
expressed by the smooth muscle cells within the vessel
wall and uPAR was preferentially expressed by endothe-
lial cells.
In situ hybridization for uPA and uPAR mRNA
Next, in situ hybridization for uPA and uPAR mRNA
was performed on all biopsies (N  47) to confirm the
cellular source of uPA and uPAR (Fig. 4 G to L). Control
biopsies (obtained from transplant patients without re-
jection) showed positive staining for uPA in only a lim-
ited amount of proximal tubular cells as expected from
the literature (Fig. 4G) [14]. These biopsies were nega-
tive for uPAR (Fig. 4J).
In type I rejection, the mononuclear infiltrate showed
strong positive staining for both uPA (Fig. 4H) and
uPAR (Fig. 4K). Also, the tubular epithelium displayed
strong uPA and uPAR expression during rejection. In
addition, in the vascular types of rejection, strong expres-
sion of uPA was seen in the entire wall of the involved
vessels (Fig. 4I), while uPAR was expressed by the endo-
thelium (Fig. 4L).
DISCUSSION
Beside their well-described role in fibrinolysis, uPA
and its receptor uPAR are involved in other important
biologic processes such as inflammation, tissue remodel-
ing, angiogenesis, and tumor metastasis. In this study,
we demonstrate a clear systemic and local production of
uPAR associated with high expression of uPA and uPAR
in the kidney in patients with acute renal allograft rejec-
tion.
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Fig. 3. Levels of urokinase plasminogen activator receptor (uPAR) in
serum (A) and urine (B). Serum and urine levels of uPAR were deter-
mined by enzyme-linked immunosorbent assay (ELISA). Results are
displayed as mean  SEM of the individual serum (A) and urine
(B) concentrations of uPAR in transplant patients without rejection,
transplant patients with acute rejection type 1, 2, and 3, and healthy
subjects. Serum and urine levels of uPAR correspond with severity of
rejection. *P  0.05 compared to the nonrejection group; **P  0.05
compared to the control group of healthy volunteers. Both P values
were determined by analysis of variance (ANOVA), followed by a
Dunnett T3 post hoc test.
High serum levels of soluble uPAR have been re-
ported in patients with sepsis [35], advanced malignan-
cies [19], and in healthy volunteers after lipopolysaccha-
ride (LPS) administration [36]. As far as the systemic
production of uPAR is concerned, the cellular source of
uPAR in patients with acute renal rejection is unknown.
Beside leukocytes, endothelial cells are likely candidates.
Indeed, activation of T cells by phorbol ester, IL-2, or
via the TCR/CD3 complex causes a rapid up-regulation
of uPAR in vitro. In contrast, tumor necrosis factor-	
(TNF-	) has no effect and transforming growth factor-
1
(TGF-
1) substantially decreased uPAR expression in
activated T cells [11]. An up-regulation of uPAR has
been also reported on monocytes of healthy volunteers
receiving LPS injection and in vitro in whole blood stimu-
lation with LPS or TNF-	 [36]. Endothelial cells also
synthesize and release uPAR upon inflammation. In-
deed, after stimulation with phorbol 12-myristate 13-
acetate (PMA), endothelial cells produce appreciable
quantities of soluble uPAR in vitro [37] and we found a
distinct synthesis and expression of uPAR by endothelial
cells in the kidney during vascular rejection.
Variations in immunosuppressive regimens are un-
likely to account for the differences in uPA and uPAR
secretion and expression because no differences were
found between patients from the same group that were
treated with different immunosuppressive agents. More-
over, renal biopsies obtained from patients with acute
rejection treated with basiliximab, prednisone, and my-
cophenolate mofetil displayed similar uPA and uPAR
expression as acute rejection patients who were treated
with cyclosporine, prednisone, and mycophenolate mo-
fetil (data not shown).
Transplant patients without rejection also have sig-
nificantly higher levels of uPAR in blood compared to
healthy volunteers, although uPAR mRNA was not de-
tected by in situ hybridization in renal biopsies of these
patients. On the one hand, this might reflect an increased
systemic synthesis and release of uPAR due to higher
circulating levels of inflammatory cytokines in patients
with renal transplantation compared to healthy volun-
teers [38, 39]. On the other hand, renal filtration of solu-
ble uPAR might be impared in transplant patients with-
out rejection. This can contribute to increased serum
levels of soluble uPAR. Along this line, we found a
significant correlation between serum levels of uPAR
and serum creatinine. This might reflect a higher synthe-
sis of uPAR due to the severe inflammatory state (acute
rejection) combined with a decreased filtration of uPAR.
uPAR was also dramatically increased in urine during
renal rejection and this increase was significantly corre-
lated with the severity of the rejection. The release of
uPAR in the urine might be caused by leakage of uPAR
by the tubuli that are damaged during rejection. Indeed,
as shown by in situ hybridization and immunostaining,
uPAR was strongly expressed by inflammatory cells and
damaged tubuli during rejection. In vitro, tubular epithe-
lial cells secrete uPAR upon stimulation with inflamma-
tory cytokines such as TNF-	 and IL-1
 [30]. During
vascular rejection episodes, endothelial cells also synthe-
size and express uPAR. A similar up-regulation of uPAR
expression by immunostaining has been reported in sev-
eral renal diseases such as chronic allograft nephropathy
[32], thrombotic microangiopathy [26], chronic pyelone-
phritis [30], and nephrototoxic serum sickness [27]. The
pattern of uPA expression during renal rejection was
comparable to that observed for uPAR. This colocaliza-
tion of uPA and uPAR suggests interactions between
both molecules during rejection. Indeed, it has been
shown that uPA and uPAR are able to up-regulate their
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Fig. 4. Immunostaining and in situ hybridization for urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR).
Immunostaining (A to F) (red staining with blue hematoxylin counterstaining) and mRNA in situ hybridization (G to L ) (blue staining with picro
sirius red counterstaining) results for uPA (A, B, C, G, H, and I) and uPAR (D, E, F, J, K, and L) in nonrejected transplants (A, D, G, and J),
type I rejection (B, E, H, and K) and vascular rejection (C, F, I, and L). Nonrejected grafts show no expression of uPA/uPAR with immunostaining
(A and D). In situ hybridization shows mRNA expression of uPA in a limited number of tubular epithelial cells (G, arrows), and no mRNA
expression of uPAR (J) in nonrejected grafts. In type I rejection, the activated lymphocytes show strong positive staining for both uPA and uPAR
protein with immunostaining and mRNA using in situ hybridization (B, E, H, and K). Since the overall staining intensity of the in situ hybridization
for uPAR was less than for uPA, an inset was placed in (K). Furthermore, the tubular epithelial cells show positive staining for uPA in type I
rejection (B and H). In the vascular types of rejection, strong expression of uPA is seen in the entire wall of the involved vessels (C and I), while
uPAR is expressed by the endothelium (F and L) [original magnifications 200 and 400 (C, F, I, and L)].
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expression reciprocally in human kidney cells, mono-
cytes, and endothelial cells [40, 41].
Whether activation of the uPA/uPAR system exerts
detrimental or beneficial effects during renal allograft
rejection remains to be elucidated. The possible detri-
mental effects of uPA and uPAR during rejection are
related to their proinflammatory properties. Indeed,
binding of uPA to uPAR results in the generation of
cell surface-associated plasmin, which is critical for peri-
cellular proteolysis, an essential step in the migration of
inflammatory cells [42]. Independently of plasmin gener-
ation, uPAR exerts a crucial role in transendothelial
migration of monocytes through the formation of com-
plexes with the 
2 integrin CD11b/CD18 [43]. Moreover,





and those uPAR-integrin interaction may mediate cell-
cell interaction [15]. Finally, uPA exerts chemotactic ac-
tivities [44].
Apart from its proinflammatory role, the uPA/uPAR
system may to some extent protect the kidney from in-
jury. Indeed, through the generation of plasmin, uPA
and uPAR participate in the digestion of fibrin, which
is known to accumulate during renal injury and to be
deleterious for the kidney [29, 45, 46]. Moreover, uPA
is able to directly degrade some matrix components such
as fibronectin [47] and to activate latent MMPs, which
promote degradation of ECM [48]. In addition, uroki-
nase is implicated in the posttranslational activation of
several growth factors, including TGF-
1 and hepatocyte
growth factor (HGF) [49, 50]. Studies involving a mouse
model of heart transplantation have shown that cardiac
allografts are able to produce uPA, tPA, and active
TGF-
. These studies provide considerable evidence
that uPA, through plasmin-dependent TGF-
 activation,
can cause delayed-type hypersensitivity [51]. Thus, uPA
might have the ability to control donor-reactive cell-
mediated immunity and lead to rejection.
Since TGF-
1 and HGF are critical regulators of ECM
accumulation that function in an opposite manner, the
precise effect of urokinase in tissue remodeling and fi-
brosis remains unclear. Indeed, it has been recently re-
ported that uPAR deficiency accelerates renal fibrosis
[abstract; Zhang G et al, J Am Soc Nephrol 12:722, 2001]
but tPA deficiency reduces renal fibrosis [52] in the same
mouse model of chronic obstructive nephropathy. More-
over, tPA-based therapy has been reported to reduce
the glomerular matrix accumulation in an experimental
model of glomerulonephritis [53].
CONCLUSION
The present study shows strong local up-regulation
of the uPA/uPAR system during acute renal allograft
rejection. Future studies in animal models will be re-
quired to determine the pathophysiologic significance of
uPA and uPAR in renal inflammation and fibrosis, be-
fore the fibrinolytic system could serve as a target for
therapeutic interventions during acute renal rejection
and eventually for the prevention of chronic allograft
nephropathy.
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